PL3236991T3 - Pochodne fgf21 i ich zastosowania - Google Patents
Pochodne fgf21 i ich zastosowaniaInfo
- Publication number
- PL3236991T3 PL3236991T3 PL15817847T PL15817847T PL3236991T3 PL 3236991 T3 PL3236991 T3 PL 3236991T3 PL 15817847 T PL15817847 T PL 15817847T PL 15817847 T PL15817847 T PL 15817847T PL 3236991 T3 PL3236991 T3 PL 3236991T3
- Authority
- PL
- Poland
- Prior art keywords
- fgf21 derivatives
- fgf21
- derivatives
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14199935 | 2014-12-23 | ||
EP15817847.5A EP3236991B1 (en) | 2014-12-23 | 2015-12-22 | Fgf21 derivatives and uses thereof |
PCT/EP2015/080969 WO2016102562A1 (en) | 2014-12-23 | 2015-12-22 | Fgf21 derivatives and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3236991T3 true PL3236991T3 (pl) | 2019-12-31 |
Family
ID=52130150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15817847T PL3236991T3 (pl) | 2014-12-23 | 2015-12-22 | Pochodne fgf21 i ich zastosowania |
Country Status (26)
Country | Link |
---|---|
US (3) | US9744213B2 (pl) |
EP (1) | EP3236991B1 (pl) |
JP (1) | JP6727210B2 (pl) |
KR (1) | KR102427527B1 (pl) |
CN (1) | CN107108709B (pl) |
AR (1) | AR103246A1 (pl) |
AU (1) | AU2015371056B2 (pl) |
BR (1) | BR112017011552A2 (pl) |
CA (1) | CA2972128A1 (pl) |
DK (1) | DK3236991T3 (pl) |
ES (1) | ES2742503T3 (pl) |
HK (1) | HK1246156B (pl) |
HR (1) | HRP20191292T1 (pl) |
HU (1) | HUE044783T2 (pl) |
IL (1) | IL252438B (pl) |
MX (1) | MX2017007458A (pl) |
MY (1) | MY181181A (pl) |
PL (1) | PL3236991T3 (pl) |
PT (1) | PT3236991T (pl) |
RS (1) | RS59154B1 (pl) |
RU (1) | RU2729011C2 (pl) |
SA (1) | SA517381673B1 (pl) |
SI (1) | SI3236991T1 (pl) |
TW (2) | TWI681966B (pl) |
WO (1) | WO2016102562A1 (pl) |
ZA (1) | ZA201703768B (pl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018014023A (es) | 2016-05-24 | 2019-04-04 | Novo Nordisk As | Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos. |
CN106421753A (zh) * | 2016-10-19 | 2017-02-22 | 哈尔滨医科大学 | 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用 |
TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Mic-1化合物及其用途 |
JP6852939B2 (ja) * | 2017-09-04 | 2021-03-31 | 89バイオ リミテッド89Bio Ltd. | 変異体fgf−21ペプチドコンジュゲート及びその使用 |
CN114903978A (zh) | 2018-07-03 | 2022-08-16 | 百时美施贵宝公司 | Fgf-21配制品 |
US11427623B1 (en) | 2019-05-28 | 2022-08-30 | 89Bio Ltd. | Methods of treatment using mutant FGF-21 peptide conjugates |
WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
JP2024517329A (ja) | 2021-05-11 | 2024-04-19 | サイトカイ・ファーマ・アーペーエス | インターロイキン-22の治療的誘導体 |
EP4089108A1 (en) | 2021-05-11 | 2022-11-16 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
WO2024008904A2 (en) | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
EP1329227A1 (en) | 2002-01-22 | 2003-07-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells |
CN1802386B (zh) | 2003-06-12 | 2010-12-15 | 伊莱利利公司 | Glp-1类似物融合蛋白质 |
WO2005028516A2 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
US20070203058A1 (en) | 2003-09-19 | 2007-08-30 | Novo Nordisk A/S | Novel Glp-1 Derivatives |
EP2270163A1 (en) * | 2003-12-10 | 2011-01-05 | Eli Lilly and Company | Muteins of fibroblast growth factor 21 |
RU2006120077A (ru) | 2003-12-18 | 2008-01-27 | Ново Нордиск А/С (DK) | Аналоги глюкагоноподобного пептида-1 (glp-1), связанные с альбуминоподобными агентами |
JP2007531715A (ja) | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合fgf−21化合物 |
PT1751184E (pt) * | 2004-05-13 | 2009-11-10 | Lilly Co Eli | Proteínas de fusão de fgf-21 |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
BRPI0512988A (pt) * | 2004-07-08 | 2008-04-22 | Novo Nordisk As | método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica |
EP1789443A1 (en) | 2004-09-02 | 2007-05-30 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
ES2332057T3 (es) | 2004-09-02 | 2010-01-25 | Eli Lilly And Company | Muteinas del factor de crecimiento de fibroblastos 21. |
HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
EP1831371A2 (en) | 2004-12-14 | 2007-09-12 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
US20080261875A1 (en) | 2005-01-21 | 2008-10-23 | Eli Lilly And Company | Method For Treating Cardiovascular Disease |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
EP2101822A2 (en) | 2007-01-18 | 2009-09-23 | Novo Nordisk A/S | Use of peptides in combination with surgical intervention for the treatment of obesity |
WO2008121563A2 (en) | 2007-03-30 | 2008-10-09 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
CN101663046B (zh) | 2007-03-30 | 2017-07-28 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
WO2009020802A2 (en) | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
CN100587073C (zh) | 2008-03-24 | 2010-02-03 | 吉林农大生物反应器工程有限公司 | 人成纤维细胞生长因子-21的重组表达 |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
SG195542A1 (en) * | 2008-10-10 | 2013-12-30 | Amgen Inc | Fgf21 mutants and uses thereof |
WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
RU2525393C2 (ru) * | 2009-01-23 | 2014-08-10 | Ново Нордиск А/С | Производные fgf21 со связующим альбумина а-в-с-d-e- и их применение |
TWI560197B (en) | 2009-05-05 | 2016-12-01 | Amgen Inc | Fgf21 mutants and uses thereof |
CA2760674A1 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
WO2011154349A2 (en) * | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
US20120035099A1 (en) * | 2009-06-11 | 2012-02-09 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
CN102802657A (zh) | 2009-06-11 | 2012-11-28 | 诺沃-诺迪斯克有限公司 | 用于治疗2型糖尿病的glp-1和fgf21组合 |
JP6069198B2 (ja) * | 2010-07-20 | 2017-02-01 | ノヴォ ノルディスク アー/エス | N末端が修飾されたfgf21化合物 |
US20140213512A1 (en) * | 2011-08-31 | 2014-07-31 | Amgen Inc. | Method of Treating or Ameliorating Type 1 Diabetes Using FGF21 |
MX2015002985A (es) * | 2012-09-07 | 2015-06-22 | Sanofi Sa | Proteinas de fusion para el tratamiento de un sindrome metabolico. |
CN108888757A (zh) * | 2012-12-27 | 2018-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法 |
-
2015
- 2015-12-22 TW TW104143111A patent/TWI681966B/zh active
- 2015-12-22 AU AU2015371056A patent/AU2015371056B2/en active Active
- 2015-12-22 MX MX2017007458A patent/MX2017007458A/es active IP Right Grant
- 2015-12-22 CA CA2972128A patent/CA2972128A1/en active Pending
- 2015-12-22 SI SI201530859T patent/SI3236991T1/sl unknown
- 2015-12-22 AR ARP150104256A patent/AR103246A1/es active IP Right Grant
- 2015-12-22 CN CN201580069436.9A patent/CN107108709B/zh active Active
- 2015-12-22 BR BR112017011552-2A patent/BR112017011552A2/pt active Search and Examination
- 2015-12-22 RU RU2017125050A patent/RU2729011C2/ru active
- 2015-12-22 HU HUE15817847 patent/HUE044783T2/hu unknown
- 2015-12-22 MY MYPI2017701848A patent/MY181181A/en unknown
- 2015-12-22 WO PCT/EP2015/080969 patent/WO2016102562A1/en active Application Filing
- 2015-12-22 RS RSP20191106 patent/RS59154B1/sr unknown
- 2015-12-22 PL PL15817847T patent/PL3236991T3/pl unknown
- 2015-12-22 KR KR1020177017682A patent/KR102427527B1/ko active IP Right Grant
- 2015-12-22 ES ES15817847T patent/ES2742503T3/es active Active
- 2015-12-22 PT PT15817847T patent/PT3236991T/pt unknown
- 2015-12-22 TW TW108144310A patent/TWI708781B/zh active
- 2015-12-22 EP EP15817847.5A patent/EP3236991B1/en active Active
- 2015-12-22 JP JP2017533789A patent/JP6727210B2/ja active Active
- 2015-12-22 DK DK15817847.5T patent/DK3236991T3/da active
-
2017
- 2017-03-08 US US15/453,617 patent/US9744213B2/en active Active
- 2017-05-22 IL IL252438A patent/IL252438B/en unknown
- 2017-06-01 ZA ZA2017/03768A patent/ZA201703768B/en unknown
- 2017-06-06 SA SA517381673A patent/SA517381673B1/ar unknown
- 2017-07-07 US US15/643,543 patent/US9895417B2/en active Active
- 2017-12-21 US US15/849,920 patent/US10124039B2/en active Active
-
2018
- 2018-04-30 HK HK18105587.8A patent/HK1246156B/zh unknown
-
2019
- 2019-07-17 HR HRP20191292TT patent/HRP20191292T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279663A (en) | N4-hydroxycytidine, history and related antiviral uses | |
HK1225383A1 (zh) | 二氮雜環庚烷衍生物及其用途 | |
HK1231471A1 (zh) | -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途 | |
IL252216B (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
HK1246156B (zh) | Fgf21衍生物及其用途 | |
IL247822A0 (en) | History of Tubolisin | |
PL3152226T3 (pl) | Modyfikowane cyklopentapeptydy i ich zastosowania | |
SG11201609490QA (en) | Polymer-flavonoid conjugate and uses thereof | |
IL254241A0 (en) | Etv2 and its uses | |
AP2016009545A0 (en) | Naphthyridinedione derivatives | |
HK1232211A1 (zh) | 二甲基吡啶胺衍生物及其醫藥用途 | |
AP2016009530A0 (en) | Cycloalkyl-linked diheterocycle derivatives | |
PL3119744T3 (pl) | Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu | |
IL251289A0 (en) | New peptide derivatives and their use | |
PT3166945T (pt) | Derivados de triazolopirimidinona ou de triazolopiridinona inovadores e utilização dos mesmos | |
AU358334S (en) | Pants |